Emerging therapeutic opportunities for skeletal restoration

Nature Reviews Drug Discovery

Volumn 10, Issue 2, 2011, Pages 141-156

  Kawai, Masanobu ^a,b   Mödder, Ulrike I ^c   Khosla, Sundeep ^c   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; CENTCHROMAN; CONJUGATED ESTROGEN; DENOSUMAB; ESTRADIOL; ESTROGEN; IBANDRONIC ACID; IDOXIFENE; INSULIN; LASOFOXIFENE; LITHIUM SALT; MONOCLONAL ANTIBODY; ODANACATIB; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT SOMATOMEDIN C; RISEDRONIC ACID; SCLEROSTIN ANTIBODY; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; BREAST CANCER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; FLUSHING; FRAGILITY FRACTURE; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOTENSION; JAW OSTEONECROSIS; LOW DRUG DOSE; MASTALGIA; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SPINE FRACTURE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REGENERATION; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 79551610971     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3299     Document Type: Review

References (176)

1. Becker, D. J., Kilgore, M. L. & Morrisey, M. A. The societal burden of osteoporosis. Curr. Rheumatol. Rep. 12, 186-191 (2010).
2. Harralson, R. H. & Zuckerman, J. D. Prevalence, Health care expenditures, And orthopedic surgery workforce for musculoskeletal conditions. JAMA 302, 1586-1587 (2009).
3. Rosen, C. J. Bone remodeling, Energy metabolism, And the molecular clock. Cell Metab. 7, 7-10 (2008).
4. Rosen, C. J. & Bouxsein, M. L. Mechanism of disease: is osteoporosis the obesity of bone? Nature Clin. Pract. Rheumatol. 2, 35-43 (2006).
5. Manolagas, S. C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137 (2000).
6. Jansen, J. P., Bergman, G. J., Huels, J. & Olson, M. The efficacy of bisphosphonates in the prevention of vertebral, Hip, And nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin. Arthritis Rheum. 9 Sep 2010 (doi:10.1016/j. Semarthrit.2010.06.001).
7. Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nature Med. 15, 757-765 (2009).
8. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
9. Cauley, J. A. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729-1738 (2003).
10. Prestwood, K. M., Kenny, A. M., Kleppinger, A. & Kulldorff, M. Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 290, 1042-1048 (2003).
11. Ettinger, B. et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet. Gynecol. 104, 443-451 (2004).
12. McDonnell, D. P. Mining the complexities of the estrogen signaling pathways for novel therapeutics. Endocrinology 144, 4237-4240 (2003).
13. Seeman, E., Crans, G. G., Diez-Perez, A., Pinette, K. V. & Delmas, P. D. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos. Int. 17, 313-316 (2006).
14. Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the nSABP study of tamoxifen and raloxifene (StAR) P-2 trial. JAMA 295, 2727-2741 (2006).
15. Barrett-Connor, E. et al. Effects of raloxifene on cardiovasculaRevents and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137 (2006).
16. Cummings, S. R. et al. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 362, 686-696 (2010).
17. Lindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H. & Constantine, G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil. Steril. 92, 1045-1052 (2009).
18. Lobo, R. A. et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil. Steril. 92, 1025-1038 (2009).
19. Silverman, S. L. et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in post menopausal women with osteoporosis: results from a 3 year randomized, Placebo-, And active-controlled trial. J. Bone Miner. Res. 23, 1923-1934 (2008).
20. Drake, M. T., Clarke, B. L. & Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032-1045 (2008).
21. Kavanagh, K. L. et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl Acad. Sci. USA 103, 7829-7834 (2006).
22. Luckman, S. P. et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GtP-binding proteins, Including Ras. J. Bone Miner. Res. 13, 581-589 (1998).
23. Khosla, S. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22, 1479-1491 (2007).
24. Lenart, B. A. et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos. Int. 20, 1353-1362 (2009).
25. Abrahamsen, B., Eiken, P. & Eastell, R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 24, 1095-1102 (2009).
26. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
27. Riggs, B. L. The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106, 1203-1204 (2000).
28. Eghbali-Fatourechi, G. et al. Role of RAnK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111, 1221-1230 (2003).
29. Hsu, H. et al. Tumor necrosis factor receptor family member RAnK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
30. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
31. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009). Osteoporosis.
32. Brown, J. P. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, Blinded, Phase 3 trial. J. Bone Miner. Res. 24, 153-161 (2009).
33. Seeman, E. et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J. Bone Miner. Res. 25, 1886-1894 (2010).
34. Kendler, D. L. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. 25, 72-81 (2010).
35. Neville-Webbe, H. L. & Coleman, R. E. Bisphosphonates and RAnK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur. J. Cancer 46, 1211-1222 (2010).
36. Thomas, D. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, Phase 2 study. Lancet Oncol. 11, 275-280 (2010).
37. Aghaloo, T. L., Felsenfeld, A. L. & Tetradis, S. Osteonecrosis of the jaw in a patient on Denosumab. J. Oral Maxillofac. Surg. 68, 959-963 (2010).
38. McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
39. Kendler, D. L. et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int. 21, 837-846 (2010).
40. Marie P. J., Ammann, P., Boivin, G. & Rey, C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int. 69, 121-129 (2001).
41. Meunier, P. J. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459-468 (2004).
42. Rosen, C. J. The role of parathyroid hormone in the management of osteoporosis. Horm. Res. 64 (Suppl. 2), 81-85 (2005).
43. Paszty, C., Turner, C. H. & Robinson, M. K. Sclerostin: a gem from the genome leads to bone-building antibodies. J. Bone Miner. Res. 25, 1897-1904 (2010).
44. Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001).
45. Subbiah, V., Madsen, V. S., Raymond, A. K., Benjamin, R. S. & Ludwig, J. A. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos. Int. 21, 1041-1045 (2010).
46. Black, D. M. et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003).
47. Black, D. M. et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353, 555-565 (2005).
48. Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521 (2002).
49. Khosla, S., Westendorf, J. J. & Oursler, M. J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 11 8, 421-428 (2008).
50. Westendorf, J. J., Kahler, R. A. & Schroeder, T. M. Wnt signaling in osteoblasts and bone diseases. Gene 341, 19-39 (2004).
51. Hens, J. R. et al. TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J. Bone Miner. Res. 20, 1103-1113 (2005).
52. Robinson, J. A. et al. Wnt/β-catenin signaling is a normal physiological response to mechanical loading in bone. J. Biol. Chem. 281, 31720-31728 (2006).
53. Chen, Y. et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 4, E249 (2007).
54. Spencer, G. J., Utting, J. C., Etheridge, S. L., Arnett, T. R. & Genever, P. G. Wnt signalling in osteoblasts regulates expression of the receptor activator of nFκB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 119, 1283-1296 (2006).
55. Baron, R. & Rawadi, G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148, 2635-2643 (2007).
56. Van Bezooijen, R. L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, But not a classical BMP antagonist. J. Exp. Med. 199, 805-814 (2004).
57. Semenov, M., Tamai, K. & He, X. SOSt is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770-26775 (2005).
58. Poole, K. E. et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842-1844 (2005).
59. Van Bezooijen, R. L., Ten Dijke, P., Papapoulos, S. E. & Lowik, C. W. SOSt/sclerostin, An osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16, 319-327 (2005).
60. Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOSt gene product, A novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577-589 (2001).
61. Balemans, W. et al. Identification of a 52 kb deletion downstream of the SOSt gene in patients with van Buchem disease. J. Med. Genet. 39, 91-97 (2002).
62. Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOSt). Hum. Mol. Genet. 10, 537-543 (2001).
63. Staehling-Hampton, K. et al. A 52-kb deletion in the SOSt-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110, 144-152 (2002).
64. Ellies, D. L. et al. Bone density ligand, Sclerostin, Directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21, 1738-1749 (2006).
65. Li, X. et al. Sclerostin antibody treatment increases bone formation, Bone mass, And bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578-588 (2009).
66. Ominsky, M. S. et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, Bone mineral density, And bone strength. J. Bone Miner. Res. 25, 948-959 (2010).
67. Padhi, D., Jang, G., Stouch, B., Fang, L. & Posvar, E. Single-dose, Placebo-controlled, Randomized study of AMG 785, A sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26 (2011).
68. Cho, S. W. et al. Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells. Bone 44, 1069-1077 (2009).
69. Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, And targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837-851 (2009).
70. Rubin, E. M. et al. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 9, 731-741 (2010).
71. Adamska, M., MacDonald, B. T., Sarmast, Z. H., Oliver, E. R. & Meisler, M. H. En1 and Wnt7a interact with Dkk1 during limb development in the mouse. Dev. Biol. 272, 134-144 (2004).
72. Morvan, F. et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934-945 (2006).
73. Li, J. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754-766 (2006).
74. Bu, G. et al. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int. J. Cancer 123, 1034-1042 (2008).
75. Yaccoby, S. et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109, 2106-2111 (2007).
76. Heath, D. J. et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 24, 425-436 (2009).
77. Wang, F. S. et al. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40, 485-492 (2007).
78. Qian, J. et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110, 1587-1594 (2007).
79. Gregory, C. A. et al. Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J. Biol. Chem. 280, 2309-2323 (2005).
80. Glinka, A. et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391, 357-362 (1998).
81. Gonzalez-Sancho, J. M. et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/tCF and is downregulated in human colon cancer. Oncogene 24, 1098-1103 (2005).
82. Aguilera, O. et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1α, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28, 1877-1884 (2007).
83. Aguilera, O. et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25, 4116-4121 (2006).
84. Sato, H. et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 28, 2459-2466 (2007).
85. Christiansen, C., Baastrup, P. C. & Transbol, I. Development of 'primary' hyperparathyroidism during lithium therapy: longitudinal study. Neuropsychobiology 6, 280-283 (1980).
86. Christiansen, C., Baastrup, P. C., Lindgreen, P. & Transbol, I. Endocrine effects of lithium: II. 'Primary' hyperparathyroidism. Acta Endocrinol. (Copenh.) 88, 528-534 (1978).
87. Mak, T. W., Shek, C. C., Chow, C. C., Wing, Y. K. & Lee, S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J. Clin. Endocrinol. Metab. 83, 3857-3859 (1998).
88. Mallette, L. E. & Eichhorn, E. Effects of lithium carbonate on human calcium metabolism. Arch. Intern. Med. 146, 770-776 (1986).
89. Mallette, L. E., Khouri, K., Zengotita, H., Hollis, B. W. & Malini, S. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J. Clin. Endocrinol. Metab. 68, 654-660 (1989).
90. Nordenstrom, J., Elvius, M., Bagedahl-Strindlund, M., Zhao, B. & Torring, O. Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism 43, 1563-1567 (1994).
91. Clement-Lacroix, P. et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl Acad. Sci. USA 102, 17406-17411 (2005).
92. Lewicki, M., Paez, H. & Mandalunis, P. M. Effect of lithium carbonate on subchondral bone in sexually mature Wistar rats. Exp. Toxicol. Pathol. 58, 197-201 (2006).
93. Zamani, A., Omrani, G. R. & Nasab, M. M. Lithium's effect on bone mineral density. Bone 44, 331-334 (2009).
94. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Reduced relative risk of fractures among users of lithium. Calcif. Tissue Int. 77, 1-8 (2005).
95. Bolton, J. M. et al. Fracture risk from psychotropic medications: a population-based analysis. J. Clin. Psychopharmacol. 28, 384-391 (2008).
96. Wilting, I. et al. Lithium use and the risk of fractures. Bone 40, 1252-1258 (2007).
97. Kawai, M. & Rosen, C. J. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J. Cell Biochem. 111, 14-19 (2010).
98. Kawai, M. & Rosen, C. J. Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr. Nephrol. 24, 1277-1285 (2009).
99. Niu, T. & Rosen, C. J. The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene 361, 38-56 (2005).
100. Bikle, D. et al. The skeletal structure of insulin-like growth factor I-deficient mice. J. Bone Miner. Res. 16, 2320-2329 (2001).
101. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. & Efstratiadis, A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59-72 (1993).
102. Yakar, S. et al. Normal growth and development in the absence of hepatic insulin-like growth factor, I. Proc. Natl Acad. Sci. USA 96, 7324-7329 (1999).
103. Yakar, S. et al. Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110, 771-781 (2002).
104. Zhang, M. et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277, 44005-44012 (2002).
105. Zhao, G. et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141, 2674-2682 (2000).
106. Wang, Y. et al. Role of IGF-I signaling in regulating osteoclastogenesis. J. Bone Miner. Res. 21, 1350-1358 (2006).
107. Mathews, L. S. et al. Growth enhancement of transgenic mice expressing human insulin-like growth factor, I. Endocrinology 123, 2827-2833 (1988).
108. He, J., Rosen, C. J., Adams, D. J. & Kream, B. E. Postnatal growth and bone mass in mice with IGF-I haploinsufficiency. Bone 38, 826-835 (2006).
109. Hwa, V., Oh, Y. & Rosenfeld, R. G. Insulin-like growth factor binding proteins: a proposed superfamily. Acta Paediatr. Suppl. 88, 37-45 (1999).
110. Jones, J. I. & Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16, 3-34 (1995).
111. Firth, S. M. & Baxter, R. C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23, 824-854 (2002).
112. Khosla, S. et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J. Clin. Invest. 101, 2165-2173 (1998).
113. Conover, C. A. et al. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm. IGF Res. 12, 178-183 (2002).
114. Grinspoon, S., Thomas, L., Miller, K., Herzog, D. & Klibanski, A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab. 87, 2883-2891 (2002).
115. Ghiron, L. J. et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J. Bone Miner. Res. 10, 1844-1852 (1995).
116. Boonen, S. et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, Placebo-controlled pilot study. J. Clin. Endocrinol. Metab. 87, 1593-1599 (2002).
117. Fulzele, K. et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309-319 (2010).
118. Ferron, M. et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142, 296-308 (2010).
119. Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nature Med. 15, 757-765 (2009).
120. Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105, 20764-20769 (2008).
121. Kawai, M., Devlin, M. J. & Rosen, C. J. Fat targets for skeletal health. Nature Rev. Rheumatol. 5, 365-372 (2009).
122. Hauschka, P. V., Lian, J. B., Cole, D. E. & Gundberg, C. M. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol. Rev. 69, 990-1047 (1989).
123. Murshed, M., Schinke, T., McKee, M. D. & Karsenty, G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J. Cell Biol. 165, 625-630 (2004).
124. Delmas, P. D. Biochemical markers of bone turnover. J. Bone Miner. Res. 8 (Suppl. 2), 549-555 (1993).
125. Boskey, A. L. et al. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23, 187-196 (1998).
126. Lee, N. K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469 (2007).
127. Ferron, M., Hinoi, E., Karsenty, G. & Ducy, P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl Acad. Sci. USA 105, 5266-5270 (2008).
128. Hinoi, E. et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J. Cell Biol. 183, 1235-1242 (2008).
129. Strapazzon, G., De toni, L. & Foresta, C. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos. Int. 17 Jun 2010 (doi:10.1007/s00198-010- 1322-2).
130. Yeap, B. et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, Hyperglycemia and triglyceride levels. Eur. J. Endocrinol. 163, 265-272 (2010).
131. Saleem, U., Mosley, T. H. Jr & Kullo, I. J. Serum osteocalcin is associated with measures of insulin resistance, Adipokine levels, And the presence of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 30, 1474-1478 (2010).
132. Shea, M. K. et al. γ-Carboxylation of osteocalcin and insulin resistance in older men and women. Am. J. Clin. Nutr. 90, 1230-1235 (2009).
133. Pittas, A. G., Harris, S. S., Eliades, M., Stark, P. & Dawson-Hughes, B. Association between serum osteocalcin and markers of metabolic phenotype. J. Clin. Endocrinol. Metab. 94, 827-832 (2009).
134. Kindblom, J. M. et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J. Bone Miner. Res. 24, 785-791 (2009).
135. Tontonoz, P. & Spiegelman, B. M. Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 77, 289-312 (2008).
136. Rosen, E. D. & MacDougald, O. A. Adipocyte differentiation from the inside out. Nature Rev. Mol. Cell Biol. 7, 885-896 (2006).
137. Kawai, M., Sousa, K. M., MacDougald, O. A. & Rosen, C. J. The many facets of PPARγ: novel insights for the skeleton. Am. J. Physiol. Endocrinol. Metab. 299, E3-E9 (2010).
138. Iwamoto, Y. et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with nIDDM. Diabetes Care 14, 1083-1086 (1991).
139. Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I. & Horikoshi, H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37, 1549-1558 (1988).
140. Ciaraldi, T. P., Gilmore, A., Olefsky, J. M., Goldberg, M. & Heidenreich, K. A. In vitro studies on the action of CS-045, A new antidiabetic agent. Metabolism 39, 1056-1062 (1990).
141. Suter, S. L., Nolan, J. J., Wallace, P., Gumbiner, B. & Olefsky, J. M. Metabolic effects of new oral hypoglycemic agent CS-045 in nIDDM subjects. Diabetes Care 15, 193-203 (1992).
142. Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M. & Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193 (1994).
143. Schwartz, A. V. et al. Thiazolidinedione use and bone loss in older diabetic adults. J. Clin. Endocrinol. Metab. 91, 3349-3354 (2006).
144. Grey, A. et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, Controlled trial. J. Clin. Endocrinol. Metab. 92, 1305-1310 (2007).
145. Yaturu, S., Bryant, B. & Jain, S. K. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30, 1574-1576 (2007).
146. Akune, T. et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113, 846-855 (2004).
147. Kawai, M. et al. A circadian-regulated gene, Nocturnin, Promotes adipogenesis by stimulating PPAR-γ nuclear translocation. Proc. Natl Acad. Sci. USA 107, 10508-10513 (2010).
148. Krause, U. et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc. Natl Acad. Sci. USA 107, 4147-4152 (2010).
149. Botolin, S. & McCabe, L. R. Inhibition of PPARγ prevents type I diabetic bone marrow adiposity but not bone loss. J. Cell Physiol. 209, 967-976 (2006).
150. Wan, Y., Chong, L. W. & Evans, R. M. PPAR-γ regulates osteoclastogenesis in mice. Nature Med. 13, 1496-1503 (2007).
151. Wei, W. et al. PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11, 503-516 (2010).
152. Kawai, M. & Rosen, C. J. Minireview: a skeleton in serotonin's closet? Endocrinology 151, 4103-4108 (2010).
153. Garfield, A. S. & Heisler, L. K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 587, 49-60 (2009).
154. Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu. Rev. Med. 60, 355-366 (2009).
155. Gaspar, P., Cases, O. & Maroteaux, L. The developmental role of serotonin: news from mouse molecular genetics. Nature Rev. Neurosci. 4, 1002-1012 (2003).
156. Jonnakuty, C. & Gragnoli, C. What do we know about serotonin J. Cell Physiol. 217, 301-306 (2008).
157. Furness, J. B. & Costa, M. Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. Neuroscience 7, 341-349 (1982).
158. Walther, D. J. et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299, 76 (2003).
159. Yadav, V. K. et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135, 825-837 (2008).
160. Yadav, V. K. & Karsenty, G. Leptin-dependent co-regulation of bone and energy metabolism. Aging (Albany NY) 1, 954-956 (2009).
161. Howard, L., Kirkwood, G. & Leese, M. Risk of hip fracture in patients with a history of schizophrenia. Br. J. Psychiatry 190, 129-134 (2007).
162. Halbreich, U. & Palter, S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr. Bull. 22, 447-454 (1996).
163. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif. Tissue Int. 82, 92-101 (2008).
164. Diem, S. J. et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167, 1240-1245 (2007).
165. Liu, B. et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351, 1303-1307 (1998).
166. Richards, J. B. et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 167, 188-194 (2007).
167. Ziere, G. et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J. Clin. Psychopharmacol. 28, 411-417 (2008).
168. Calarge, C. A., Zimmerman, B., Xie, D., Kuperman, S. & Schlechte, J. A. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J. Clin. Psychiatry 71, 338-347 (2010).
169. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238-246 (1989).
170. Bostwick, J. R., Guthrie, S. K. & Ellingrod, V. L. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29, 64-73 (2009).
171. Yadav, V. K. et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nature Med. 16, 308-312 (2010).
172. Rosen, C. J. & Khosla, S. Placebo-controlled trials in osteoporosis -proceeding with caution. N. Engl. J. Med. 363, 1365-1367 (2010).
173. Bone, H. G. et al. Odanacatib, A cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2010).
174. Strewler, G. J. The physiology of parathyroid hormone-related protein. N. Engl. J. Med. 342, 77-85 (2000).
175. Horwitz, M. J. et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J. Clin. Endocrinol. Metab. 95, 1279-1287 (2010).
176. Horwitz, M. J., Tedesco, M. B., Gundberg, C., Garcia-Ocana, A. & Stewart, A. F. Short-term, High-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88, 569-575 (2003).